Recent Efforts to Develop Imaging Methods and β -Cell-Specific Contrast Agents for Non-Invasive in vivo Assessment of β-Cell Mass

Author(s): Stephan Schneider, John Virostko, Astrid Reimann, Alvin C. Powers

Journal Name: Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
Continued as New Advances on Endocrine Metabolic and Immune Diseases

Volume 3 , Issue 3 , 2009


Accurate, non-invasive assessment of the endogenous pancreatic β-cell mass in humans is currently not feasible. The development of a non-invasive assay of β-cell mass would be invaluable in the study of the natural course of diabetes and ongoing attempts to preserve or restore β-cell mass in patients with diabetes. This article reviews imaging methods and radiolabeled ligands which have been proposed or used for non-invasive assessment of the endogenous β- cell mass and discusses patents and future directions for the development of β-cell specific contrast agents.

Keywords: Non-invasive imaging, β-cell mass, imaging probes, BLI, MRI, PET

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Published on: 01 March, 2012
Page: [157 - 161]
Pages: 5
DOI: 10.2174/187221409789104737
Price: $65

Article Metrics

PDF: 3